Compounds > arsenic
Page last updated: 2024-08-26

arsenic and azacitidine

arsenic has been researched along with azacitidine in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (54.55)29.6817
2010's10 (45.45)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
List, AF1
Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S1
Giles, FJ; Jabbour, EJ1
Fukumoto, JS; Greenberg, PL1
Pu, Q1
Benbrahim-Tallaa, L; Boos, J; Liu, J; Qian, X; Qu, W; Waalkes, MP; Xie, Y; Yu, L1
Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS1
Craig, CM; Schiller, GJ1
Eblin, KE; Futscher, BW; Gandolfi, AJ; Jensen, TJ; Novak, P1
Chang, H; Chen, G; Feng, Y; Huang, H; Lin, F; Sun, A; Wang, Y; Wu, D1
Bartlett, DL; Gorry, MC; Guo, ZS; Li, Q; O'Malley, ME1
Gotlib, J; Greenberg, PL1
Jiang, J; Liu, XS; Peng, CY; Zheng, HT1
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE1
Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P1
Guo, LP; Li, LW; Li, XY; Lu, SX; Yu, XY; Zhou, Y1
Luo, JM; Sun, J; Zhang, XK1
Chan, TS; Chau, D; Cheng, YY; Fong, B; Kwong, YL; Ng, K; Tam, S; Tse, E1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E1
Feng, L; Li, XY; Li, Y; Liu, X; Wang, X; Zhang, L1
Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J1
Chiu, JF; Huang, N; Li, G; Lin, W; Pei, X; Tao, T1

Reviews

5 review(s) available for arsenic and azacitidine

ArticleYear
New approaches to the treatment of myelodysplasia.
    The oncologist, 2002, Volume: 7 Suppl 1

    Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome

2002
New agents in myelodysplastic syndromes.
    Current hematology reports, 2005, Volume: 4, Issue:3

    Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Apoptosis; Arsenicals; Azacitidine; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytokines; DNA Methylation; Enzyme Inhibitors; Farnesyltranstransferase; Growth Substances; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Myelodysplastic Syndromes; Oligonucleotides, Antisense; Piperazines; Prognosis; Pyrimidines; Treatment Outcome

2005
Management of patients with higher risk myelodysplastic syndromes.
    Critical reviews in oncology/hematology, 2005, Volume: 56, Issue:2

    Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Azacitidine; Combined Modality Therapy; Disease-Free Survival; Farnesyltranstransferase; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Oxides; Prognosis; Risk Factors; Treatment Outcome

2005
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
    Blood reviews, 2008, Volume: 22, Issue:4

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides

2008
Novel biospecific agents for the treatment of myelodysplastic syndromes.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2003, Volume: 1, Issue:4

    Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide

2003

Trials

2 trial(s) available for arsenic and azacitidine

ArticleYear
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
    Cancer investigation, 2011, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib

2011
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
    American journal of hematology, 2011, Volume: 86, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult

2011

Other Studies

15 other study(ies) available for arsenic and azacitidine

ArticleYear
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
    Blood, 2004, Jan-01, Volume: 103, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2004
[Further improving the standard of treatment for chronic myeloid leukemia].
    Zhonghua nei ke za zhi, 2006, Volume: 45, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha

2006
Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells.
    Toxicology and applied pharmacology, 2006, Nov-01, Volume: 216, Issue:3

    Topics: Animals; Arsenic; Arsenites; Azacitidine; Blotting, Western; Carcinogens; Cell Cycle; Cell Line; Cell Transformation, Neoplastic; Dealkylation; Decitabine; DNA, Neoplasm; Gene Expression; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Growth; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stress, Physiological

2006
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2007, Volume: 38, Issue:1

    Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides

2007
Epigenetic remodeling during arsenical-induced malignant transformation.
    Carcinogenesis, 2008, Volume: 29, Issue:8

    Topics: Acetylation; Arsenicals; Azacitidine; Cell Line; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; Environmental Exposure; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Teratogens; Urinary Bladder Neoplasms; Urothelium

2008
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
    European journal of haematology, 2009, Volume: 82, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Oxides; RNA, Messenger; Transcription, Genetic; Xenograft Model Antitumor Assays

2009
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms.
    Molecular pharmacology, 2009, Volume: 76, Issue:5

    Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Genes, Homeobox; Growth Inhibitors; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Male; Mice; Oxides; Pyridines; Transcription Factors; Up-Regulation

2009
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:2

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid

2010
[Mechanism of loss of human esophageal cancer-related gene 4 (ECRG4) gene expression in esophageal squamous cell carcinoma cell line EC9706].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Esophageal Neoplasms; Exons; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Oxides; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins

2011
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:2

    Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; K562 Cells; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; TYK2 Kinase

2014
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
    Journal of hematology & oncology, 2015, May-08, Volume: 8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aquaporins; Arsenic Trioxide; Arsenicals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Oxides; Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation

2015
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14

    Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid

2017
The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
    Oncology reports, 2017, Volume: 38, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Tumor; Cell Survival; DNA (Cytosine-5-)-Methyltransferase 1; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Oxides; Wnt Signaling Pathway

2017
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, Dec-28, Volume: 268

    Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution

2017
DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells.
    Acta biochimica et biophysica Sinica, 2018, Aug-01, Volume: 50, Issue:8

    Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Transformed; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation; Lung; NAD(P)H Dehydrogenase (Quinone); Oxides; Promoter Regions, Genetic; Rats

2018